In 1994 I was diagnosed with celiac disease, which led me to create Celiac.com in 1995. I created this site for a single purpose: To help as many people as possible with celiac disease get diagnosed so they can begin to live happy, healthy gluten-free lives. Celiac.com was the first site on the Internet dedicated solely to celiac disease, and since then it has become an invaluable resource to people worldwide who seek information about celiac disease and the gluten-free diet.
In 1998 I created The Gluten-Free Mall, Your Special Diet Superstore! which was also another Internet first—it was the first gluten-free food site to offer a shopping cart-style interface, and the ability for people to order gluten-free products manufactured by many different companies at a single Web site.
I am also co-author of the book Cereal Killers, and founder and publisher of Journal of Gluten Sensitivity.
Gene Ther 2003 May;10(10):835-43
Londei M, Quaratino S, Maiuri L.
Institute of Child Health, University College London, London, UK.
Celiac.com 05/29/2003 - This highly technical and hopeful article covers the possibility of using gene therapy to one day cure celiac disease. Here are the introduction and final words:
"Gene therapy (GT) is still at the experimental stage and some recent setbacks have cooled the potential use of this therapeutic tool even in life-threatening conditions. However, this therapeutic approach has a potential, which is not limited to disease for which we have not other option. There are increasing evidence that GT will be soon used in diseases that are not life threatening. One group of diseases that can benefit from GT is the autoimmune one. Several experimental animal models have indicated the efficacy (proof of principle) of GT. In the present review, we have addressed the possibility that even extremely benign autoimmune-like diseases such as Celiac Disease (CD) might one day profit from this type of therapy. We further point that in conditions such as CD, where the trigger is well known and the pathogenic cascade is relatively well defined, a situation not common in autoimmunity, we can even have a better situation where to explore and use GT to control disease initiation and progression. Once the risks that are still intrinsic to GT will have been reduced the therapeutic options we outline in the present review might not appear too far from reality."
"CD is the prototype of diseases in which a clear role of antigen-specific
T cells has been demonstrated and where their inhibition results in disease
amelioration. The present therapeutic approach is the removal of the antigenic
challenge: the gluten-free diet, which is effective if there is a strict
compliance to the diet. It is, however, not always easy to follow such
strict restrictions for all life and alternative approaches have to be
considered. The use of GT is at the moment a remote hypothesis as celiac disease is
a relatively benign condition, with a valid therapeutic approach and GT
has intrinsic risks that have been highlighted recently. The scope of
this review is, however, to indicate a future application of GT when,
as they will, the present limitations and intrinsic risks of GT will be